BMS-955176 HCl hydrate

GSK3532795 (also known as BMS-955176) is a potent oral second-generation HIV-1 maturation inhibitor (MI) that has advanced to phase IIb clinical trials. This compound exhibits broad coverage against polymorphic viruses (EC50 < 15 nM, covering common polymorphisms representing 96.5% of HIV-1 subtype B) and demonstrates favorable pharmacokinetic properties in preclinical species.

N(CCN1CCS(=O)(=O)CC1)[C@]23[C@@]([C@@]4([C@@](C)(CC2)[C@@]5(C)[C@](CC4)([C@]6(C)[C@@](CC5)(C(C)(C)C(=CC6)C7=CC=C(C(O)=O)C=C7)[H])[H])[H])([C@H](C(C)=C)CC3)[H].Cl.O